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A B S T R A C T
Anti-Helicobacter pylori IgG serum levels were
measured in 31 young male bronchiectasis
patients without gastrointestinal symptoms, and
56 healthy males. The possible presence of
H. pylori was also investigated by rapid urease
tests, culture and histopathological examination
of protected catheter brush and biopsy specimens
from the bronchiectatic site. No serological,
microbiological or histological evidence of
H. pylori infection was found in the bronchiectasis
patient group. H. pylori did not appear to be an
agent of infection or chronic colonisation in
bronchiectasis, and may not have a significant
role in the progression of this disease.
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It has been suggested that Helicobacter pylori has a
role in the development of gastritis [1], peptic ulcer
[1] and gastric lymphoma [2], and that it is also
associated with ischaemic heart disease [3], cere-
brovascular disease [3] and rosacea [4,5]. The
presence of H. pylori at sites other than gastric
mucosa has not been shown clearly in humans, but
strains of H. pylori isolated from saliva and dental
plaque are generally identical to those isolated
from the stomach [6,7], and it is possible that
H. pylori might be introduced into the lung via
aspiration of saliva and gastric contents. H. pylori
has been isolated from tracheal secretions [8], and
the possible relationship between bronchiectasis
and H. pylori has been investigated by serological
tests [9,10]. The aim of the present study was to
evaluate whether H. pylori exists in the lung or is a
cause of infection in patients with bronchiectasis.
Thirty-one male patients with bronchiectasis
and 56 healthy controls were enrolled. Patients
with a history of disease that could be associated
with H. pylori (e.g., gastritis, peptic ulcer, gastric
lymphoma, coronary artery disease), other lung
diseases or antibiotic use during the previous
month were excluded. The study was approved
by the Hospital Research Committee, and
informed consent was obtained from all subjects.
Bronchiectasis was diagnosed by thorax high-
resolution computerised tomography (Somatom
DR-H; Siemens, Munich, Germany). Age and
smoking history (i.e., smoker or non-smoker)
were recorded, but other demographics were
not recorded since all subjects were white male
soldiers and shared virtually the same living
conditions. Spirometric functions, such as forced
vital capacity, forced expiratory volume in 1 s, as
a percentage of the predicted value (Spiromate
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AS600; Riko, Minato, Japan), and 24-h sputum
volumes were measured [11]. The number of
bronchiectatic lobes was determined with high-
resolution computerised tomography. Blood sam-
ples were taken on the day of bronchoscopy, and
sera were stored at )40 C.
Microbiological samples were obtained by
protected brush (Bard Endoscopic Technologies,
Billerica, MA, USA) from one of the bronchiectatic
lobes or segments, using a fibreoptic broncho-
scope (Pentax FB-18x; Asahi Optical, Tokyo,
Japan). Three bronchial mucosa biopsy samples
were obtained with fenestrated biopsy forceps
(Pentax KW2211S; Asahi Optical). One sample
was used to determine urease activity as des-
cribed previously [12]. Mayer’s haematoxylin–
eosin and Giemsa stain methods were used for
histopathological evaluation of the presence of
H. pylori in the second mucosa sample. H. pylori
culture was performed on the protected-brush
sample and the third mucosa sample as follows.
Biopsy specimens were crushed in sterile saline
with a glass rod and homogenised by vortexing.
The protected brush sample was vortexed in
sterile saline to create a homogeneous suspension.
The suspensions were inoculated in parallel on
selective and non-selective media. The selective
medium was brain–heart infusion agar with
defibrinated horse blood 7% v ⁄v, plus IsoVitaleX
(Becton Dickinson, Franklin Lakes, NJ, USA) 1%
v ⁄ v, vancomycin 3 mg ⁄L, colistin 7.5 mg ⁄L and
nystatin 12 500 U ⁄L. The non-selective medium
did not contain antimicrobials. Plates were incu-
bated at 37 C for 7 days in a moist micro-aerobic
atmosphere with oxygen 5–7% v ⁄v (CampyGen;
Oxoid, Basingstoke, UK). Gram-negative,
catalase-positive and urease-positive organisms
were identified presumptively as H. pylori [13,14].
Anti-H. pylori IgG levels were measured with
the Quorum EIA H. pylori IgG kit (Quorum
Diagnostics, Vancouver, Canada), following the
manufacturer’s instructions. Anti-H. pylori IgG
levels ‡ 20 U ⁄mL were considered positive, while
values < 15 U ⁄mL were considered negative.
Between these thresholds, results were consid-
ered indeterminate. Comparison of patients and
controls was by unpaired-samples t-test. The chi-
square test was used to compare seropositivity
rates. Logistic regression analysis was used to
assess the relationship between the serum anti-
H. pylori IgG status of the patients (as the
dependent variable) and smoking, forced vital
capacity, forced expiratory volume in 1 s, 24-h
sputum volume and the number of lung lobes
with bronchiectasis (as independent variables).
p values < 0.05 were considered significant.
The age range of the bronchiectasis patients
was 20–27 years (mean ¼ 22.0, SD ± 1.9 years),
while the control group had an age range of 20–
26 years (mean ¼ 21.6, SD ± 1.4 years). Sixteen
(51.6%) patients were smokers. Five patients did
not have a chronic sputum complaint, but
26 patients had sputum production varying from
1 to 70 mL daily (mean 12.5 mL, SD ± 15.9 mL).
The mean ± SD forced vital capacity and forced
expiratory volume in 1 s readings were
61.9 ± 10.4 and 57.3 ± 13.7, respectively. Ten
patients had only one bronchiectatic lobe, 11
patients had two, six patients had three, and the
four remaining patients had four bronchiectatic
lobes (mean 2.1; SD ± 1.0).
The urease test was negative in all patients, and
H. pylori was not isolated from protected brush or
bronchial mucosa biopsy samples. A chronic non-
specific inflammation was reported following
histopathological examination of most biopsy
specimens, but H. pylori was not detected. Anti-
H. pylori IgG levels were positive in 18 (58.1%)
patients and 38 (67.9%) control subjects. Two
patients and two controls gave indeterminate
results. Anti-H. pylori IgG levels (mean ± SD) in
the patients and controls were 45.4 ± 49.8 and
Table 1. Clinical characteristics of
the patients with bronchiectasisClinical
characteristics
H. pylori-
seronegative
patients
H. pylori-
seropositive
patients
All patients with
bronchiectasis
Smokers (%) 61.5 44.4 51.6
Sputum volume (mL ⁄ 24 h) 9.5 ± 11.7 14.7 ± 18.4 12.5 ± 15.9
FVC 64.6 ± 9.8 60.0 ± 10.7 61.9 ± 10.4
FEV1 58.4 ± 14.0 56.5 ± 13.8 57.3 ± 13.7
Lung lobes with
bronchiectasis
2.2 ± 1.2 2.1 ± 0.9 2.1 ± 1.0
Data are presented as mean ± SD, except for the smokers percentages.
FVC, forced vital capacity; FEV1 forced expiratory volume in 1 s.
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52.6 ± 52.8 U ⁄mL, respectively. These differences
were not significant (p 0.55 and p 0.52, respect-
ively). Table 1 summarises the clinical character-
istics of bronchiectasis patients in relation to the
serology results. The relationships between
H. pylori seropositivity, age and gender were not
studied, since all the patients were male and
belonged to a narrow age range. No relationship
was found between H. pylori seropositivity and
the clinical characteristics studied (Table 2).
Although the existence of H. pylori in the lungs
has been reported previously [8], specimens in the
present study were collected from the tracheal
tubes, rather than directly from lung tissue, and
bacteriological culture was not used. Tsang et al.
[9] reported that anti-H. pylori IgG occurrence and
antibody concentrations were significantly higher
in patients with bronchiectasis when compared
with tuberculosis patients and healthy controls. A
subsequent study reported similar results for
antibodies directed against the H. pylori cytotox-
in-associated gene A (CagA) [10]. However, only
serological tests were used in these two studies.
In the present study, urease tests applied to
fresh bronchial biopsy specimens were nega-
tive, H. pylori was not isolated from culture of
protected brush specimens or bronchial mucosa
biopsies, and H. pylori could not be detected
histologically in bronchial mucosa biopsies.
It has been speculated that H. pylori might play
a role in the initial phase and the progression of
acquired bronchiectasis. However, seropositivity
rates and antibody levels were lower in the
patient group than in the controls, although the
values obtained from the control group were in
accordance with the findings of previous studies
carried out in Turkey [15,16]. Antibiotic treatment
of patients with bronchiectasis may lead to the
low seropositivity and IgG levels seen in these
patients.
The present study group was relatively small,
but large groups are difficult to enrol as invasive
bronchoscopy procedures need patient consent
and the preparation of specialised H. pylori media.
Nevertheless, H. pylori was not identified from any
specimens obtained from the bronchiectatic air-
ways, and H. pylori seropositivity was not related
to any clinical parameter investigated. Although a
definitive conclusion is still not possible, H. pylori
was not present in the lungs of this group of young
male patients with bronchiectasis, but without
gastrointestinal symptoms, and did not seem to be
responsible for chronic colonisation, infection or
the progression of the disease.
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Clinical characteristics
Odds
ratio 95% CI p
Smoking (smoker,
non-smoker)
3.65 0.65–20.51 0.14
Sputum volume (mL ⁄ 24 h) 1.03 0.97–1.10 0.29
FVC 0.91 0.80–1.02 0.10
FEV1 1.05 0.96–1.14 0.33
Number of bronchiectatic
lobes
0.71 0.32–1.57 0.40
FVC, forced vital capacity; FEV1 forced expiratory volume in 1 s.
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A B S T R A C T
The antimicrobial susceptibility patterns of 73
glycopeptide-resistant Enterococcus faecalis isolates
from nine hospitals in Brazil were analysed by the
disk diffusion method and Etests. Isolates were
typed by pulsed-field gel electrophoresis (PFGE),
and vancomycin resistance genes were detected
by PCR. The isolates shared a single major PFGE
pattern, with six subtypes, and all were positive
for vanA. These results indicate the occurrence of
inter-hospital dissemination of glycopeptide-
resistant E. faecalis in Sa˜o Paulo, and raise con-
cerns about the rapid dissemination of this
pathogen throughout Brazil.
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Enterococci have been isolated with increasing
frequency from nosocomial infections over the
past two decades. These opportunistic pathogens
represent a frequent cause of infection in patients
hospitalised for long periods or in patients receiv-
ing multiple courses of antimicrobial therapy [1].
The percentage of nosocomial infections in the
USA caused by glycopeptide-resistant enterococci
(GRE) increased from 0.3% in 1989 to 25.9% in
1999 [2]. The SENTRY Antimicrobial Surveillance
Program identified an increase in the prevalence
of glycopeptide resistance among clinical isolates
of enterococci in the USA and Latin America,
from 14% and 0% in 1997, to 17% and 2% in
1999, respectively [3].
There are important differences in the epidemi-
ology of GRE in the USA and Europe [4,5]. In the
USA, the high incidence of infections with GRE has
been attributed to the extensive use of vancomycin
in hospitals [6]. In contrast, infections with GRE
and outbreaks occur less frequently in most west-
ern European countries, although GRE have been
identified among healthy individuals, as well as in
raw sewage and farm animals [7]. These epidemi-
ological differences might be associated with use of
the glycopeptide avoparcin as a growth promoter
for food animals in some European countries.
However, this agent has not been approved for use
as an animal growth promoter in the USA, and has
not been used in Brazil since 1998 [4,7,8].
The first glycopeptide-resistant Enterococcus
strain isolated in Brazil was a strain of E. faecium
of the vanD genotype [9]. Later, several hospitals
located in Sa˜o Paulo and other Brazilian cities
reported outbreaks and isolated cases of infection
or colonisation with GRE [10,11]. Initially, most
reports were of E. faecium, but dissemination of
glycopeptide-resistant E. faecalis (GREf) has since
occurred in some Brazilian cities [11,12]. The
objective of the present study was to characterise
GREf isolates collected in Sa˜o Paulo hospitals and
to evaluate the dissemination of GREf clones
among Brazilian hospitals.
In total, 73 GREf isolates were collected from
patients hospitalised at the following Brazilian
hospitals: Hospital Sa˜o Paulo (n ¼ 36); Hospital do
Rim e Hipertensa˜o (n ¼ 10); Hospital Oswaldo
Cruz (n ¼ 7); Hospital 9 de Julho (n ¼ 6); Hospital
Bandeirantes (n ¼ 7); Hospital do Servidor Pu´blico
Estadual (n ¼ 4); Hospital Santa Paula (n ¼ 1);
Hospital Unimed Sorocaba (n ¼ 1); and Hospital
Santa Marcelina (n ¼ 1). One isolate ⁄patient was
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